NCT07037680CompletedPhase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Efficiency and Safety of Radiotherapy Combined With Anlotinib in Locally Advanced Non-small Cell Lung Cancer Patients Intolerable to Concurrent Chemoradiotherapy: A Phase II Single-arm Trial
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- First submitted
- 28 May 2025
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- JIANYANG WANG
- Diseases
- Lung cancer
- NCT number
- NCT07037680
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 44
- From 1 Jan 2024 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- currently receiving treatment for malignancies at other sites, except for curable non-melanoma skin cancer and cervical carcinoma in situ;
Other illness
- previous malignancy within five years;
- thoracic radiotherapy history, hemoptysis, myocardial infarction or cerebrovascular accident within three months;
Other
- uncontrolled or active pulmonary inflammation;
- participated in other clinical trials;
- Pregnant women.
Who the study is looking for
- ≥18 years old with no restrictions on sex;
- Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;
- Eastern cooperative oncology group (ECOG) score ≤2 was required;
- Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;
- .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk;
- No symptoms of hemoptysis;
- Adequate hepatic and renal functions with a negative urine protein;
- Expected survival of more than 6 months.
Criteria the registry did not label
- Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK/ROS1-mutated locally advanced unresectable NSCLC were screened.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiation Oncology,Cancer Institute and Hospital,Chinese Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.